• Valneva reported five-year study results today showing sustained antibody responses following a single dose of its chikungunya vaccine IXCHIQ.
• Older adults showed antibody persistence comparable to younger adults, supporting the vaccine’s potential for long-term protection.
• Participants will be followed for up to 10 years to assess the durability of immune responses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valneva SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100100PRIMZONEFULLFEED1001302694) on November 10, 2026, and is solely responsible for the information contained therein.